Roche Holding AG stock climbs as oncology pipeline gains ESMO focus

Published on 10/29/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding AG stock traded at EUR 435.55 with Lang & Schwarz on October 29. Roche's ESMO update adds detail on late-stage cancer programs.

Pipeline and trading context

Roche previewed late-stage oncology data covering divarasib, giredestrant and Tam-Peli.
The company is targeting up to 20 potential new medicines by 2030.
Roche reaffirmed its 2026 outlook for mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates.

Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche Holding AG stock traded at EUR 435.55 with Lang & Schwarz on October 29, 2026, at 17:09 Berlin time. That was 1.59% above the EUR 428.75 quote reported in the latest reviewed article dated October 28. The comparison is separate from any Xetra daily performance measure.

Roche's October 19 announcement previewed new oncology data for the European Society for Medical Oncology meeting in Madrid. The company said phase III Krascendo 1 results showed divarasib outperforming first-generation KRAS G12C inhibitors in previously treated advanced non-small-cell lung cancer. It also highlighted patient-reported outcomes from the phase III lidERA study of giredestrant in early-stage breast cancer and phase III data for the investigational antibody-drug conjugate Tam-Peli in nasopharyngeal carcinoma.

The announcement came from Roche, which said the ESMO material was intended to demonstrate the breadth of its late-stage portfolio. The update does not provide a sales forecast for these individual programs, so their commercial contribution remains dependent on further development and regulatory decisions.

What matters for investors

The pipeline update adds detail to Roche's broader operating backdrop. In its October 22 sales update, Roche reported nine-month group sales of CHF 46.493 billion, up 6% at constant exchange rates and 1% in Swiss francs. Pharmaceuticals generated CHF 36.212 billion, up 7% at constant exchange rates, while Diagnostics contributed CHF 10.281 billion, up 4% on that basis.

Roche reaffirmed its 2026 outlook for mid-single-digit group-sales growth and high-single-digit core earnings-per-share growth at constant exchange rates, alongside a further dividend increase in Swiss francs. Management also said the group aims to bring up to 20 new medicines to patients by 2030. For investors, the key question is whether this pipeline can offset pressure from competition and patent expiries as development programs progress.

The continuously updated real-time quote of Roche Holding AG stock shows the latest market snapshot.